Together, these results show for the first time that low-dose IL-2 treatment in PBMCs from CKD patients specifically expands Tregs in vitro, and these results imply that low-dose IL-2 administration could modify endogenous peripheral Tregs from CKD patients. This evidence concerns the gene IL2 and chronic kidney disease.